IDH2 and acute myeloid leukemia: In the present study, we aimed to evaluate the use of LNA-qPCR assay to monitor MRD after treatment in AML patients harboring IDH1-R132, IDH2-R140, or IDH2-R172 mutations, to correlate the MRD results of IDH1/2 mutations with those of NPM1 mutations, and to determine their impact on the outcome.